Literature DB >> 19619188

Midazolam as a sole sedative for computed tomography imaging in pediatric patients.

Ranju Singh1, Nishant Kumar, Homay Vajifdar.   

Abstract

OBJECTIVE: To evaluate the efficacy and adverse effects of i.v. midazolam as a sole agent for sedation in children for computed tomography (CT) imaging.
MATERIALS AND METHODS: Prospective clinical trial in which 516 children under ASA classification II-IV (273 boys and 243 girls) in the age group of 6 months to 6 years for elective CT scan were enrolled over a 17-month period. Patients were administered i.v. midazolam 0.2 mg x kg(-1) and further boluses of 0.1 mg x kg(-1) (total 0.5 mg x kg(-1)) if required. Measurements included induction time, efficacy, side effects, complications, and degree of sedation. Sedation was graded on the basis of Ramsay sedation score (RSS) as over sedated (RSS 5-6), adequately sedated (AS, RSS 3-4), under sedated (RSS 1-2), or failed if the procedure could not be completed or another agent had to be administered.
RESULTS: Of the 516 procedures, 483 brains, 16 chests, and 17 abdomens were scanned with a mean duration of 4.75 +/- 1.75 min with a mean dose of 0.212 mg x kg(-1) of i.v. midazolam. Four hundred and sixty-five (90.12%) patients were AS in 5.9 +/- 0.7 min while 40 (7.75%) patients required additional boluses. Of these 40 patients, 24 (4.65%) required a single bolus, 12 (2.32%) required two boluses, whereas the remaining four (0.78%) required three boluses. In 11 (2.13%; P < 0.0001) patients, the scan could not be completed satisfactorily. Side effects were seen in 46 (9.11%) patients in the form of desaturation, hiccups (seven patients, 1.38%), and agitation (four patients, 0.79%). Desaturation (SpO2 90-95%) was seen in 35 (6.93%) patients, which was corrected by topical application of oxygen. None of the patients exhibited any complications such as pulmonary aspiration or need to maintain airway. The patients were kept under observation for 1 h after the procedure.
CONCLUSION: The level of sedation achieved in children with midazolam 0.2 mg x kg(-1) is adequate for imaging with minimal side effects, no airway complications, and fast recovery. It can be recommended as the sole agent for sedation in pediatric patients for CT imaging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19619188     DOI: 10.1111/j.1460-9592.2009.03084.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  6 in total

1.  Barbiturate Induction for the Prevention of Emergence Agitation after Pediatric Sevoflurane Anesthesia.

Authors:  Tadasuke Use; Haruna Nakahara; Ayako Kimoto; Yuki Beppu; Maki Yoshimura; Toshiyuki Kojima; Taku Fukano
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Sep-Oct

Review 2.  Sedation and anesthesia for CT: emerging issues for providing high-quality care.

Authors:  Charles G Macias; Corrie E Chumpitazi
Journal:  Pediatr Radiol       Date:  2011-08-17

3.  Paediatric sedation for imaging is safe and effective in a district general hospital.

Authors:  Mark A Bailey; Arun Saraswatula; Gemma Dale; Laura Softley
Journal:  Br J Radiol       Date:  2016-03-09       Impact factor: 3.039

4.  Intramuscular midazolam for pediatric sedation in the emergency department: a short communication on clinical safety and effectiveness.

Authors:  Mohammad Reza Ghane; Seyed Yasin Musavi Vaezi; Amir Abbas Hedayati Asl; Hamid Reza Javadzadeh; Sadrollah Mahmoudi; Amin Saburi
Journal:  Trauma Mon       Date:  2012-05-26

5.  Comparing Two Different Doses of Intravenous Midazolam in Pediatric Sedation and Analgesia.

Authors:  Hassan Barzegari; Kambiz Masoumi; Hassan Motamed; Behzad Zohrevandi; Shima Zeynadini Meymand
Journal:  Emerg (Tehran)       Date:  2016-11

6.  Oral Midazolam-Ketamine versus Midazolam alone for Procedural Sedation of Children Undergoing Computed Tomography; a Randomized Clinical Trial.

Authors:  Saeed Majidinejad; Keramat Taherian; Mehrdad Esmailian; Mehdi Khazaei; Vajihe Samaie
Journal:  Emerg (Tehran)       Date:  2015
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.